The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2025 | Outcomes with ven-based therapy in 1L or 2L high-risk CLL/SLL: a real-world international study
Catherine Coombs, MD, UC Irvine Health, Orange County, CA, discusses an international study evaluating the real-world treatment outcomes of patients with high-risk chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) receiving venetoclax (ven)-based therapy in the first-line (1L) or second-line (2L) setting. Although longer-term follow-up data are needed, Dr Coombs highlights that the efficacy of these regimens was promising in this patient population. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2025 in Krakow, Poland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So I’ll be presenting a poster looking at some real-world outcomes from patients who have higher-risk CLL, which is either unmutated IGHV and or TP53 aberrations, whether that’s a mutation in the gene or 17p deletion. And this was a large effort among 20-some academic institutions, mostly academic, all participating in this collaborative group called CORE...
So I’ll be presenting a poster looking at some real-world outcomes from patients who have higher-risk CLL, which is either unmutated IGHV and or TP53 aberrations, whether that’s a mutation in the gene or 17p deletion. And this was a large effort among 20-some academic institutions, mostly academic, all participating in this collaborative group called CORE. And so what we show is that you can actually attain pretty excellent outcomes even among high-risk patients who are treated in the front line with venetoclax-based regimens, most typically venetoclax with obinutuzumab, and we also look at this in the second line. Of course, longer follow-up is needed to understand the durability of these responses, but overall encouraging, suggesting that it is a reasonable approach to treat even the highest-risk patients with a time-limited regimen.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
AbbVie, AstraZeneca, BeOne Medicines, Lilly, Genentech, Janssen.
